Illumina (ILMN) Proxy filing summary

Executive summary

• Returned to growth in 2025, with $4.34B revenue and improved profitability, driven by strong adoption of the NovaSeq X platform and expansion in multiomics and data platforms.

• Achieved milestones including the acquisition of SomaLogic and launch of Bioinsight, supporting clinical and biopharma partners.

• Board succession plan advanced, with three directors concluding service and a new nominee, David P. King, proposed for election.

• Maintained strong balance sheet, generated $931M in free cash flow, and returned $740M to stockholders via share repurchases.

Voting matters and shareholder proposals

• Stockholders will vote to elect nine directors, ratify Ernst & Young LLP as auditor for FY2026, and approve executive compensation on an advisory basis.

• Board recommends voting FOR all nominees and proposals.

• Proxy access allows groups of up to 20 stockholders owning 3%+ for 3 years to nominate directors.

Board of directors and corporate governance

• Board consists of nine nominees with diverse expertise in healthcare, finance, technology, and governance.

• All directors except the CEO are independent; Board committees are 100% independent.

• Annual director elections, majority vote standard, and proxy access in place.

• Board leadership includes an independent Chair and annual evaluations of Board and committee effectiveness.